AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31479411 — intervention group
Group type: COMPARATOR
Intervention: Corners
Number of subjects: 10
Study 29447787 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 3000
Study 29447787 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus P2Y12 inhibitor (DAPT)
Number of subjects: 3000
Study 27061246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PD/A
Number of subjects: 71
Study 27061246 — intervention group
Group type: COMPARATOR
Intervention: Comparison group without an axis I disorder
Number of subjects: 71
Study 24195609 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR) for 6 months
Number of subjects: 39
Study 24195609 — intervention group
Group type: COMPARATOR
Intervention: Control group (A or B, not specified)
Number of subjects: 39
Study 21457605 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-group
Number of subjects: 11
Study 21457605 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 11
Study 19480887 — intervention group
Group type: EXPERIMENTAL
Intervention: Families and Schools Together (FAST) program
Number of subjects: 67
Study 19480887 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing school services)
Number of subjects: 67
Study 17173219 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 7 days
Number of subjects: 0
Study 17173219 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 14 days
Number of subjects: 0
Study 17173219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with metronidazole and azithromycin
Number of subjects: 0
Study 17173219 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15209319 — intervention group
Group type: EXPERIMENTAL
Intervention: Long distance group (36 km)
Number of subjects: 21
Study 15209319 — intervention group
Group type: EXPERIMENTAL
Intervention: Short distance group (24 km)
Number of subjects: 21
Study 15209319 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 km)
Number of subjects: 21
Study 11397720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (low‐molecular‐mass direct thrombin inhibitor)
Number of subjects: 320
Study 11397720 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320
Study 11397720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran
Number of subjects: 320
Study 11397720 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 320
Study 9418683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dong quai
Number of subjects: 71
Study 9418683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 8494138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 30
Study 8494138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 2967187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10-20 mg o.d.
Number of subjects: 59
Study 2967187 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR 20-40 mg b.i.d.
Number of subjects: 59
Study 31228189 — intervention group
Group type: EXPERIMENTAL
Intervention: alert-based computerized decision support (CDS)
Number of subjects: 458
Study 31228189 — intervention group
Group type: COMPARATOR
Intervention: no notification (control)
Number of subjects: 458
Study 28329231 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 112
Study 26404105 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pre‐surgical nasoalveolar moulding (PNAM)
Number of subjects: 32
Study 26404105 — intervention group
Group type: COMPARATOR
Intervention: Hotz's plate
Number of subjects: 32
Study 24948104 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal shampoo (Acorus calamus, Phyllanthus emblica, Zanthoxylum limonella)
Number of subjects: 0
Study 24948104 — intervention group
Group type: COMPARATOR
Intervention: Carbaryl shampoo (0.6% w/v)
Number of subjects: 0
Study 24948104 — intervention group
Group type: COMPARATOR
Intervention: Malathion shampoo (1.0% w/v)
Number of subjects: 0
Study 24948104 — intervention group
Group type: COMPARATOR
Intervention: Commercial shampoos (Babi Mild Natural' N Mild, Johnson's baby shampoo)
Number of subjects: 0
Study 24948104 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal shampoos (in vivo)
Number of subjects: 0
Study 24948104 — intervention group
Group type: COMPARATOR
Intervention: Chemical shampoos (in vivo)
Number of subjects: 0
Study 24948104 — intervention group
Group type: COMPARATOR
Intervention: Commercial shampoos (in vivo)
Number of subjects: 0
Study 22755347 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure
Number of subjects: 100
Study 22755347 — intervention group
Group type: COMPARATOR
Intervention: Delayed Primary Closure
Number of subjects: 100
Study 20686410 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment (5-day course given monthly for 8 months)
Number of subjects: 100
Study 20686410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19065860 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenitally blind participants
Number of subjects: 3
Study 19065860 — intervention group
Group type: COMPARATOR
Intervention: Normally sighted participants
Number of subjects: 3
Study 19065860 — intervention group
Group type: COMPARATOR
Intervention: Late-onset blind participants
Number of subjects: 3
Study 15988425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.2 mg/kg bolus followed by 0.5 mg/kg/hour for 2 hours)
Number of subjects: 68
Study 15988425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal-saline infusion)
Number of subjects: 68
Study 12920976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil mixture supplemented (50% extra virgin olive oil and 50% soybean oil)
Number of subjects: 14
Study 12920976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14
Study 10389787 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with ropivacaine (10 mg/mL, 15-25 mL) followed by an infusion (2 mg/mL, 4-6 mL/h for 24 h, plus top-up doses of 6-10 mL for 48 h)
Number of subjects: 90
Study 10389787 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia followed by IV patient-controlled analgesia with morphine
Number of subjects: 90
Study 10389787 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with ropivacaine
Number of subjects: 90
Study 8678497 — intervention group
Group type: EXPERIMENTAL
Intervention: IA with a double-lumen reservoir (DR group)
Number of subjects: 99
Study 8678497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE group)
Number of subjects: 99
Study 8678497 — intervention group
Group type: COMPARATOR
Intervention: IA with a conventional reservoir (SR group)
Number of subjects: 99
Study 8678497 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir patency
Number of subjects: 99
Study 1653578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg die) for 6 months
Number of subjects: 10
Study 1653578 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 10
Study 7080881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (vodka and tonic, 1:5 ratio, mean blood alcohol level of .064%)
Number of subjects: 0
Study 7080881 — intervention group
Group type: COMPARATOR
Intervention: Alcohol expectancy (placebo beverage: water and tonic, 1:5 ratio)
Number of subjects: 0
Study 31970898 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT) requiring leaning and reaching, 10-12 sessions of 30-45 minutes each
Number of subjects: 76
Study 31970898 — intervention group
Group type: COMPARATOR
Intervention: Control group with trunk restrained performing VRT with small upper extremity movements, 10-12 sessions of 30-45 minutes each
Number of subjects: 76
Study 31233639 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 107
Study 31233639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 28571235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 28571235 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 26143402 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 26143402 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study 24411424 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Training Group (n = 9, Group A)
Number of subjects: 17
Study 24411424 — intervention group
Group type: COMPARATOR
Intervention: Standard Training Group (n = 8, Group B)
Number of subjects: 17
Study 22045156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PG) 300 mg orally before surgery and 150 mg twice a day for 48 hours postoperatively
Number of subjects: 60
Study 22045156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PG)
Number of subjects: 60
Study 22045156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 19252826 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium intake (greater than the RDA of 55 microg/day)
Number of subjects: 23
Study 17464604 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (group E)
Number of subjects: 80
Study 17464604 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration around the hip joint with a mixture of 100 mL ropivacaine 2 mg/mL, 1 mL ketorolac 30 mg/mL, and 1 mL epinephrine 0.5 mg/mL (group A)
Number of subjects: 80
Study 15246889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71
Study 15246889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 12195326 — intervention group
Group type: EXPERIMENTAL
Intervention: Training using the GI-Mentor virtual reality endoscopy simulator for 2 hours per day for 3 weeks.
Number of subjects: 24
Study 12195326 — intervention group
Group type: COMPARATOR
Intervention: No training (control group).
Number of subjects: 24
Study 12195326 — intervention group
Group type: COMPARATOR
Intervention: Experts in gastrointestinal endoscopy.
Number of subjects: 24
Study 11189397 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 50
Study 11189397 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 7896993 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment to day hospital rehabilitation
Number of subjects: 0
Study 7896993 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment to inpatient rehabilitation
Number of subjects: 0
Study 7896993 — intervention group
Group type: COMPARATOR
Intervention: Self-selected day hospital rehabilitation
Number of subjects: 0
Study 7896993 — intervention group
Group type: COMPARATOR
Intervention: Self-selected inpatient rehabilitation
Number of subjects: 0
Study 1971028 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 103
Study 1971028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 367979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg per day for 12 months
Number of subjects: 0
Study 367979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 0
Study 367979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg per day for 6 months
Number of subjects: 0
Study 31110098 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of 4CMenB and routine vaccines
Number of subjects: 5026
Study 31110098 — intervention group
Group type: COMPARATOR
Intervention: Prior AEFI(s)
Number of subjects: 5026
Study 28316279 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban
Number of subjects: 3396
Study 28316279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 3396
Study 28316279 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg)
Number of subjects: 3396
Study 28316279 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3396
Study 26107519 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity leave educational tool
Number of subjects: 155
Study 24325695 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons (PCB)
Number of subjects: 86
Study 24325695 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloons (Control)
Number of subjects: 86
Study 21521505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid result group (PCR assay providing results on the following day)
Number of subjects: 406
Study 21521505 — intervention group
Group type: COMPARATOR
Intervention: Delayed result group (PCR assay providing results after eight to twelve days)
Number of subjects: 406
Study 21521505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid result group
Number of subjects: 406
Study 21521505 — intervention group
Group type: COMPARATOR
Intervention: Delayed result group
Number of subjects: 406
Study 18972894 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 1:400,000 (group B)
Number of subjects: 50
Study 18972894 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with adrenaline 1:400,000 (group S)
Number of subjects: 50
Study 16377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel clearance
Number of subjects: 1082
Study 16377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube management
Number of subjects: 1082
Study 16377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative recovery timeline
Number of subjects: 1082
Study 16377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ileus
Number of subjects: 1082
Study 16377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of postoperative hospital stay
Number of subjects: 1082
Study 12952703 — intervention group
Group type: EXPERIMENTAL
Intervention: JUTE model (Web-based educational model)
Number of subjects: 34
Study 12952703 — intervention group
Group type: COMPARATOR
Intervention: Control Website (information available on the Internet)
Number of subjects: 34
Study 12952703 — intervention group
Group type: EXPERIMENTAL
Intervention: JUTE model
Number of subjects: 34
Study 11003448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 24
Study 11003448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11003448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 24
Study 8820893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 1 (1690.3 kJ)
Number of subjects: 12
Study 8820893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 2 (2529.1 kJ)
Number of subjects: 12
Study 8820893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 3 (3384.3 kJ)
Number of subjects: 12
Study 8820893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trials
Number of subjects: 12
Study 1419942 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 300
Study 1419942 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle with bevel parallel to dural fibers
Number of subjects: 300
Study 1419942 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle with bevel perpendicular to dural fibers
Number of subjects: 300
Study 1419942 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 300
Study 3880715 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 80
Study 3880715 — intervention group
Group type: COMPARATOR
Intervention: End-to-side portacaval shunt
Number of subjects: 80
Study 3880715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both shunts
Number of subjects: 80
Study 30758912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 830
Study 30758912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Number of subjects: 830
Study 29954183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 10 mg/kg/d
Number of subjects: 180
Study 29954183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg/d
Number of subjects: 180
Study 29954183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg/d
Number of subjects: 180
Study 29954183 — intervention group
Group type: EXPERIMENTAL
Intervention: All rifampin doses
Number of subjects: 180
Study 27052839 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic Oscillation Stimulation (KOS) with high amplitude pressure (mean pressure of 65 mbar, pressure amplitude of 100 mbar, and 68 Hz)
Number of subjects: 207
Study 27052839 — intervention group
Group type: COMPARATOR
Intervention: Kinetic Oscillation Stimulation (KOS) with low amplitude pressure (mean pressure of 65 mbar, pressure amplitude of 4 mbar, and 68 Hz)
Number of subjects: 207
Study 27052839 — intervention group
Group type: COMPARATOR
Intervention: Uninflated balloon treatment (control group)
Number of subjects: 207
Study 25179086 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation (5 mg daily for 90 days)
Number of subjects: 102
Study 21918912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Motor Imitation Antecedent Training (RMIA) combined with parent education
Number of subjects: 5
Study 20014913 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 10
Study 20014913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17578790 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to nevirapine
Number of subjects: 52
Study 17578790 — intervention group
Group type: COMPARATOR
Intervention: Continuation of efavirenz therapy
Number of subjects: 52
Study 15626320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/mL rhBMP-2
Number of subjects: 0
Study 15626320 — intervention group
Group type: COMPARATOR
Intervention: Other concentrations of rhBMP-2
Number of subjects: 0
Study 11409559 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of bupivacaine 0.5% with epinephrine 0.0005%
Number of subjects: 320
Study 11409559 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of bupivacaine 0.5%
Number of subjects: 320
Study 11409559 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of morphine in 15 ml of isotonic saline solution
Number of subjects: 320
Study 11409559 — intervention group
Group type: COMPARATOR
Intervention: 15 ml of isotonic saline solution (control group)
Number of subjects: 320
Study 9734748 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia group (29 infants)
Number of subjects: 55
Study 9734748 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic control group (26 infants)
Number of subjects: 55
Study 16856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fiber diet (33 g pea fiber product/10 MJ)
Number of subjects: 11
Study 16856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fiber added to breakfast (12 g/10 MJ) and lunch (15 g/10 MJ)
Number of subjects: 11
Study 16856319 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 11
Study 16856319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fiber diet
Number of subjects: 11
Study 3057399 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6
Study 3057399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31704697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon graft (QT)
Number of subjects: 99
Study 31704697 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus/gracilis hamstring graft (STG)
Number of subjects: 99
Study 31704697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both graft types
Number of subjects: 99
Study 29993297 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance behavior
Number of subjects: 317
Study 29993297 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor insight
Number of subjects: 317
Study 29993297 — intervention group
Group type: EXPERIMENTAL
Intervention: Not-just-right perception
Number of subjects: 317
Study 29993297 — intervention group
Group type: EXPERIMENTAL
Intervention: Different personality traits
Number of subjects: 317
Study 26318384 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2
Number of subjects: 584
Study 26318384 — intervention group
Group type: COMPARATOR
Intervention: INF
Number of subjects: 584
Study 26089183 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 0.27 mg
Number of subjects: 319
Study 26089183 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline 0.9 mg
Number of subjects: 319
Study 26089183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 24008606 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Pycnogenol
Number of subjects: 78
Study 24008606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 21794974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers and current smokers
Number of subjects: 718
Study 21794974 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 718
Study 21794974 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 718
Study 21794974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of recurrences
Number of subjects: 718
Study 21794974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple tumors
Number of subjects: 718
Study 21794974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of intravesical therapy
Number of subjects: 718
Study 17239987 — intervention group
Group type: EXPERIMENTAL
Intervention: 1320-nm Nd:YAG laser therapy
Number of subjects: 46
Study 17239987 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated skin)
Number of subjects: 46
Study 17239987 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment surveys
Number of subjects: 46
Study 14758573 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 0
Study 14758573 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0